Chia Puey Ling, Parakh Sagun, Russell Prudence, Gan Hui K, Asadi Khashayer, Gebski Val, Murone Carmel, Walkiewicz Marzena, Liu Zhanqi, Thapa Bibhusal, Scott Fiona E, Scott Andrew M, John Thomas
Department of Medical Oncology, Austin Health, Melbourne, Australia; Olivia-Newton John Cancer Research Institute, Melbourne, Australia; Faculty of Medicine, University of Melbourne, Melbourne, Australia.
Department of Medical Oncology, Austin Health, Melbourne, Australia; Olivia-Newton John Cancer Research Institute, Melbourne, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia.
Lung Cancer. 2021 Mar;153:35-41. doi: 10.1016/j.lungcan.2020.12.028. Epub 2020 Dec 31.
Conformational forms of the epidermal growth factor receptor (EGFR) are pro-tumorigenic. The prevalence and impact of conformational forms of EGFR in malignant mesothelioma (MM) is unknown. We investigated expression of EGFR and conformational forms of EGFR by immunohistochemistry using EGFR-targeting monoclonal antibodies (mAb). In addition, EGFR gene amplification was investigated by fluorescent in-situ hybridization (FISH). Findings were correlated with survival.
Patients treated between 1988 and 2014 were identified from the thoracic surgery database of the Austin Hospital, Melbourne, Australia. Tissue microarrays (TMAs) were constructed, subjected to wild type (wt) EGFR IHC staining and FISH analysis. Conformational and mutation forms of EGFR were detected by IHC using mAb806, and LMH-151 which detects EGFRVIII. H-scores were derived and EGFR expression correlated with survival by Kaplan-Meier and log rank analysis.
WtEGFR expression was seen in 93 % (299/321) of cases with overexpression (defined as an H-score ≥200) seen in more than half of cases (64 %). EGFR overexpression in MM was seen more commonly in the epithelioid subtype. EGFR overexpression was not associated with true EGFR amplification, although multiple copies were appreciated in samples with polysomy. EGFR expression did not correlate with survival. A conformational form of EGFR associated with EGFR dysregulation was found in 8.2 % of cases, and patients with these tumors had a trend towards a poorer outcome. No cases of the EGFRVIII mutation were identified.
MM consistently demonstrated high expression of EGFR, with a subset of tumors showing conformational EGFR forms consistent with EGFR dysregulation, but withoutEGFR amplification or EGFR VIII mutation. wtEGFR expression did not influence survival. The impact of EGFR conformation on survival warrants further investigation.
表皮生长因子受体(EGFR)的构象形式具有促肿瘤生成作用。EGFR构象形式在恶性间皮瘤(MM)中的发生率及影响尚不清楚。我们使用靶向EGFR的单克隆抗体(mAb)通过免疫组织化学研究了EGFR的表达及EGFR的构象形式。此外,通过荧光原位杂交(FISH)研究了EGFR基因扩增情况。研究结果与生存率相关。
从澳大利亚墨尔本奥斯汀医院的胸外科数据库中识别出1988年至2014年期间接受治疗的患者。构建组织微阵列(TMA),进行野生型(wt)EGFR免疫组化染色和FISH分析。使用检测EGFRVIII的mAb806和LMH-151通过免疫组化检测EGFR的构象和突变形式。得出“H评分”,并通过Kaplan-Meier和对数秩分析将EGFR表达与生存率相关联。
93%(299/321)的病例可见wtEGFR表达,超过半数(64%)的病例可见过表达(定义为H评分≥200)。MM中的EGFR过表达在上皮样亚型中更常见。EGFR过表达与真正的EGFR扩增无关,尽管在多倍体样本中可观察到多个拷贝。EGFR表达与生存率无关。在8.2%的病例中发现了一种与EGFR失调相关的EGFR构象形式,患有这些肿瘤的患者预后有较差的趋势。未发现EGFRVIII突变病例。
MM始终表现出EGFR的高表达,一部分肿瘤显示出与EGFR失调一致的构象EGFR形式,但没有EGFR扩增或EGFR VIII突变。wtEGFR表达不影响生存率。EGFR构象对生存率的影响值得进一步研究。